Clin Exp Rheumatol 2018 Jul-Aug;36(4):540-544. Epub 2018 Jan 31.
Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Arthritis Res Ther 2017 Feb 10;19(1):28. Epub 2017 Feb 10.
Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Background: Three different subsets of circulating human monocytes, CD14CD16- (classical), CD14CD16+ (intermediate), and CD14CD16+ (non-classical) have been recently identified. It has been reported that CD14CD16+ monocytes are increased in rheumatoid arthritis (RA). However, the role of each monocyte subset in the pathogenesis of RA is still unclear. Read More
Pharmacol Res 2016 05 1;107:308-314. Epub 2016 Apr 1.
Department of Health Sciences, School of Medicine, University of Eastern Piedmont, Via Solaroli, 17-28100 Novara, Italy; IRCAD, School of Medicine, Novara, Italy. Electronic address:
Circulating human monocytes, a functionally and phenotypically heterogeneous population, are emerging as fundamental cell types in rheumatoid arthritis (RA). The aim of this pilot study was to assess the correlation, if any, among anti-rheumatic drug therapy, circulating CD14(+)CD16(+) monocytes and validated clinical scales (e.g. Read More
PLoS One 2012 3;7(1):e28918. Epub 2012 Jan 3.
NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom.
Objective: The expression of FcγRIIIa/CD16 may render monocytes targets for activation by IgG-containing immune complexes (IC). We investigated whether FcγRIIIa/CD16 was upregulated in rheumatoid arthritis (RA), associated with TNF production in response to IC-stimulation, and if this predicted response to methotrexate therapy.
Methods: FcγRIIIa/CD16 expression on CD14(low) and CD14++ monocytes was measured by flow cytometry in healthy controls and RA patients (early and long-standing disease). Read More
Clin Exp Immunol 2012 Oct;170(1):36-46
NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, UK.
Anti-tumour necrosis factor (TNF) biologics have revolutionized therapy of rheumatoid arthritis (RA). We compared the effects of infliximab on numbers of circulating leucocyte subsets in early RA (disease/symptom duration of ≤1 year) and late RA patients (>1 year). A control group consisted of early RA patients treated with a combination of methotrexate (MTX) and methylprednisolone. Read More